ASH1L and bone neoplasm: Pathway analysis in Fig. 6a also indicates that TAMs from ASH1L-depleted bone tumors exhibited decreased IGF downstream signaling, i.e., AKT and MAPK pathways, suggesting IGF signaling may be involved in the TAM plasticity and metabolic programming driven by ASH1L.